Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237283417> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4237283417 endingPage "S30" @default.
- W4237283417 startingPage "S12" @default.
- W4237283417 abstract "Psoriasis is a chronic, inflammatory, immune-mediated skin disease that affects roughly 2% of adults in the United States. The immunopathogenic pathways associated with psoriasis are complex, and to effectively target the underlying cytokine networks involved in disease progression, drugs are needed that act on specific components of the immune system. As understanding of the role of proinflammatory signaling molecules in the psoriatic disease process has evolved, several biologic agents have been engineered to block key cytokines associated with psoriasis. Recently, improvements in the understanding of the pathogenesis have led to the development of agents that may target the mechanism of disease more directly. This review describes the immunopathogenesis of psoriasis and how targeting disease-specific mechanisms with biologic agents may improve clinical outcomes and potentially result in better safety profiles than conventional agents. Results from pivotal clinical studies evaluating the efficacy and safety of approved tumor necrosis factor-α antagonists (etanercept, infliximab, and adalimumab) and the interleukin-12/23 inhibitor ustekinumab are summarized. In addition, we include clinical findings to date evaluating a new class of biologics that neutralize interleukin-17A (secukinumab, ixekizumab) or act as an interleukin-17 receptor antagonist (brodalumab). Finally, this review discusses efficacy and safety factors, as well as patient characteristics to consider, when selecting a biologic agent for psoriasis disease management." @default.
- W4237283417 created "2022-05-12" @default.
- W4237283417 creator A5029023097 @default.
- W4237283417 creator A5037373134 @default.
- W4237283417 date "2014-09-01" @default.
- W4237283417 modified "2023-09-25" @default.
- W4237283417 title "Biologic Agents for Moderate-to-Severe Plaque Psoriasis" @default.
- W4237283417 cites W1758502430 @default.
- W4237283417 cites W1834455687 @default.
- W4237283417 cites W1920164691 @default.
- W4237283417 cites W1983141530 @default.
- W4237283417 cites W2024249616 @default.
- W4237283417 cites W2058968313 @default.
- W4237283417 cites W2062523779 @default.
- W4237283417 cites W2080008012 @default.
- W4237283417 cites W2124011136 @default.
- W4237283417 cites W2159513688 @default.
- W4237283417 cites W2322390243 @default.
- W4237283417 doi "https://doi.org/10.1097/jdn.0000000000000082" @default.
- W4237283417 hasPublicationYear "2014" @default.
- W4237283417 type Work @default.
- W4237283417 citedByCount "0" @default.
- W4237283417 crossrefType "journal-article" @default.
- W4237283417 hasAuthorship W4237283417A5029023097 @default.
- W4237283417 hasAuthorship W4237283417A5037373134 @default.
- W4237283417 hasConcept C126322002 @default.
- W4237283417 hasConcept C156730664 @default.
- W4237283417 hasConcept C164027704 @default.
- W4237283417 hasConcept C17991360 @default.
- W4237283417 hasConcept C203014093 @default.
- W4237283417 hasConcept C2776260265 @default.
- W4237283417 hasConcept C2776914184 @default.
- W4237283417 hasConcept C2777138892 @default.
- W4237283417 hasConcept C2777226972 @default.
- W4237283417 hasConcept C2778690821 @default.
- W4237283417 hasConcept C2778975655 @default.
- W4237283417 hasConcept C2779134260 @default.
- W4237283417 hasConcept C2779745271 @default.
- W4237283417 hasConcept C2779786854 @default.
- W4237283417 hasConcept C2780132546 @default.
- W4237283417 hasConcept C2780564577 @default.
- W4237283417 hasConcept C2781228260 @default.
- W4237283417 hasConcept C71924100 @default.
- W4237283417 hasConcept C74172505 @default.
- W4237283417 hasConceptScore W4237283417C126322002 @default.
- W4237283417 hasConceptScore W4237283417C156730664 @default.
- W4237283417 hasConceptScore W4237283417C164027704 @default.
- W4237283417 hasConceptScore W4237283417C17991360 @default.
- W4237283417 hasConceptScore W4237283417C203014093 @default.
- W4237283417 hasConceptScore W4237283417C2776260265 @default.
- W4237283417 hasConceptScore W4237283417C2776914184 @default.
- W4237283417 hasConceptScore W4237283417C2777138892 @default.
- W4237283417 hasConceptScore W4237283417C2777226972 @default.
- W4237283417 hasConceptScore W4237283417C2778690821 @default.
- W4237283417 hasConceptScore W4237283417C2778975655 @default.
- W4237283417 hasConceptScore W4237283417C2779134260 @default.
- W4237283417 hasConceptScore W4237283417C2779745271 @default.
- W4237283417 hasConceptScore W4237283417C2779786854 @default.
- W4237283417 hasConceptScore W4237283417C2780132546 @default.
- W4237283417 hasConceptScore W4237283417C2780564577 @default.
- W4237283417 hasConceptScore W4237283417C2781228260 @default.
- W4237283417 hasConceptScore W4237283417C71924100 @default.
- W4237283417 hasConceptScore W4237283417C74172505 @default.
- W4237283417 hasIssue "5S" @default.
- W4237283417 hasLocation W42372834171 @default.
- W4237283417 hasOpenAccess W4237283417 @default.
- W4237283417 hasPrimaryLocation W42372834171 @default.
- W4237283417 hasRelatedWork W1970925217 @default.
- W4237283417 hasRelatedWork W2007444191 @default.
- W4237283417 hasRelatedWork W2127804484 @default.
- W4237283417 hasRelatedWork W2202409929 @default.
- W4237283417 hasRelatedWork W2324734971 @default.
- W4237283417 hasRelatedWork W2755835629 @default.
- W4237283417 hasRelatedWork W2981603084 @default.
- W4237283417 hasRelatedWork W2984218665 @default.
- W4237283417 hasRelatedWork W3042976130 @default.
- W4237283417 hasRelatedWork W4248008924 @default.
- W4237283417 hasVolume "6" @default.
- W4237283417 isParatext "false" @default.
- W4237283417 isRetracted "false" @default.
- W4237283417 workType "article" @default.